BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming investor conferences in March 2020.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 40th Annual Healthcare Conference

-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in preclinical models to inhibit the activity of TORC1 and induce autophagy in neuronal cells --

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global Healthcare Conference

Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated agreements (the “Purchase Agreements”) with a limited number of holders of Assertio’s currently outstanding 2.50% Convertible Notes due 2021 and 5.00% Convertible Senior Notes due 2024 (the “Purchased Notes”).

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020.

Company Anticipates Earlier Than Expected Preliminary Data Readout in August 2020

Blueprint Medicines Corporation announced its participation in fireside chats at the following upcoming investor conferences

BRIDGEWATER, N.J. , Feb. 19, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the 9 th Annual SVB Leerink Global Healthcare Conference in New York, NY on We

REDWOOD CITY, Calif. , Feb. 19, 2020 /PRNewswire/ -- Bolt Biotherapeutics, a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that Randall C. Schatzman , PhD., Chief Executive Officer, will present at the SVB Leerink 9 th Annual Global